I’m so glad you’re here. Glow Lab was created for women 40+ who are curious about metabolism, energy, longevity science, and peptide research. Many of us reach a point where our bodies start changing and we’re told, “That’s just aging.” Here, we explore the science behind what’s really happening and what researchers are discovering about how the body works. This community is a place for: • learning about metabolism and mitochondrial energy • exploring peptide and longevity research • asking questions and sharing discoveries • supporting each other in becoming healthier and more vibrant You don’t need to be an expert. Just bring curiosity. --- ✨ Start here with these three steps: 1️⃣ Introduce Yourself Tell us where you’re from and what made you curious about Glow Lab. 2️⃣ Visit the Classroom Go to Classroom → “Start Here: Welcome to Glow Lab” to begin the Glow Lab University lessons. 3️⃣ Check the Calendar Join our upcoming live sessions where we talk about metabolism, peptides, and longevity science together. --- 🌿 Community vibe This is a respectful, supportive space. Curiosity is encouraged, questions are welcome, and everyone is learning together. --- ✨ Introduce yourself below! Where are you joining from and what made you curious about metabolism or peptide sci

Glow family, you’re going to want to bookmark this one! 🔖 We created PepGuide.me — a new, easy-to-use place to find the peptide information you’ve been asking for, all in one spot. Inside you’ll find: 🧪 Reconstitution instructions 📖 A peptide dictionary 🌱 Beginner starting-dose guides ✨ And much more, with new resources being added Visit and bookmark it now: 👉 https://PepGuide.me Save this post and drop a 💜 below after you’ve checked it out! For educational purposes only. Information on PepGuide.me is not medical advice. Always work with a qualified healthcare professional for personalized guidance.

Leadership opportunities! We are looking for leaders who understand what it feels like to be new. Help beginners navigate our community as well answer questions and offer a warm Welcome!

https://youtu.be/vjBdynW7zns?is=4UBjPhrQeNKH-2Un

What’s actually at stake for Lilly? Today, we’re following the money—because this fight is about science, but it is also very much about business. The simple explanation Calling retatrutide a biologic would not change the molecule. It would change the legal rulebook surrounding it. Think of it like placing the same athlete into a different league. The athlete stays the same, but the contracts, protections and competition rules change. Why does Lilly want the biologic label? 1. Longer protection A qualifying new traditional drug may receive about five years of federal exclusivity. A qualifying new biologic may receive 12 years before the FDA can approve a biosimilar relying on it. (fda.gov⁠, fda.gov⁠) That is a possible seven-year advantage for Lilly. Exclusivity is not the same as a patent, and it does not block every competing medicine. But it can delay certain lower-cost versions. 2. A different type of competition Traditional drugs usually face generics. Biologics face biosimilars, which must be shown to be highly similar with no meaningful differences in safety or effectiveness. This can be a more complicated path than creating a traditional generic. (fda.gov⁠) 3. More time before possible Medicare price negotiation Under current law: - Traditional drugs may become eligible after at least seven years. - Biologics may become eligible after at least 11 years. That could give Lilly about four additional years before a Medicare-negotiated price might take effect—if retatrutide is approved, becomes a major Medicare expense and is selected for negotiation. (sec.gov⁠) 4. A stronger barrier against compounded copies Biologic status would make it harder for compounded copies to qualify under the normal drug-compounding exemptions. But here is the part social media often gets wrong: Retatrutide already cannot legally be compounded under federal law. It is not FDA approved and does not currently qualify for the federal compounding pathways. Therefore, this lawsuit would not suddenly “ban legal compounded retatrutide.” (fda.gov⁠)